文献速递胃肠动力与功能性疾病食管胃疾病与幽门螺杆菌

胰高血糖素样肽-1受体激动剂使用与食管动力异常相关并可能致病

Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With and May Lead to Esophageal Motility Abnormalities.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-11-08

本研究旨在评估GLP-1RA暴露与食管高分辨率测压(HRM)表现的相关性。GLP-1RA已知影响胃肠动力,但对食管功能直接影响了解甚少。该研究可能发现GLP-1RA使用与食管动力异常相关。

要点

  • GLP-1RA使用可能与食管动力异常相关。
  • GLP-1RA对食管功能的影响超出已知的GERD风险。
  • 需进一步研究明确因果关系。

核心结论

  • GLP-1RA使用与食管动力异常相关,并可能致病。

研究设计与样本

  • 评估GLP-1RA暴露与食管高分辨率测压(HRM)表现相关性的研究。

主要发现

  • GLP-1RA使用与食管动力异常相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for the treatment of obesity and type 2 diabetes mellitus (T2D). GLP1-RA use has grown exponentially, with a recent survey reporting 1 in 8 adults (12%) in the United States have ever taken a GLP-1RA.1 GLP-1RAs are known to cause a variety of effects on gastrointestinal motility, including increased gastric accommodation, delayed gastric motility, and decreased small intestinal transit. However, little is known regarding the direct effects of GLP-1RAs on esophageal function beyond reported increased risk of gastroesophageal reflux disease (GERD).2 The primary aim of this study was to assess the association of GLP-1RA exposure with findings on esophageal high-resolution manometry (HRM).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gala K, Camilleri M, Goyal M, et al. Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With and May Lead to Esophageal Motility Abnormalities. Clin Gastroenterol Hepatol. 2025. PMID: 41213390. doi:10.1016/j.cgh.2025.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。